A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).

Aparna R. Parikh(Massachusetts General Hospital), Theodore S. Hong(Massachusetts General Hospital), Lauren Matlack(Harvard University), Colin D. Weekes(Massachusetts General Hospital), Ryan B. Corcoran(Massachusetts General Hospital), Emily E. Van Seventer(Massachusetts General Hospital), David P. Ryan(East Carolina University), Jennifer Y. Wo(Massachusetts General Hospital), Bronwen Foreman(Harvard University), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Bruce J. Giantonio(Northwestern University), Jeffrey W. Clark(Massachusetts General Hospital), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Jill N. Allen(Harvard University), Lorraine C. Drapek(Harvard University), David T. Ting(Massachusetts General Hospital), Beow Y. Yeap(Harvard University), Leilana Ly(Harvard University)
Journal of Clinical Oncology
May 20, 2019
Cited by 46


Related Papers